Security key
019770106
Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ALLO)
CUSIP: 019770106
Q2 2026 13F Holders as of 30 Jun 2026
- Security type / class
- Equity / Common Stock, par value $0.001 per share (the "Shares")
- Total 13F shares
- 774,253
- Total 13F value
- $1,610,446
- Share change
- +759,122
- SEC-reported price per share
- $2.08
- Number of holders
- 3
- Value change
- +$1,578,974
- Number of buys
- 3
- Shares outstanding
- 244,825,714
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2026
Institutions
3
Top holders
3
ALLO full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Allogene Therapeutics, Inc. SEC filings
Allogene Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 019770106
Recent filing periods:
Ownership snapshot
Top reported holders of ALLO - Allogene Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PFIZER INC
Disclosed value leader
TPG GP A, LLC
Comparable rows
15/15
Latest evidence
16 Apr 2026
13F
13D/G
3/4/5
Lead comparable stake: 9%
13D/G row: PFIZER INC
Showing 1-6 of 15 holder rows.
Quick read
PFIZER INC leads the comparable SEC ownership view at 9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PFIZER INC's linked filing trail.
Comparable ownership
Top 5
PFIZER INC
9%
Arie Belldegrun
5.4%
BlackRock, Inc.
5.3%
David D. Chang
4.9%
FMR LLC
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PFIZER INC |
13F
13D/G
Company
|
9%
from 13D/G
|
$49,792,410
22,032,040 shares
|
— | 31 Mar 2026 |
| Arie Belldegrun |
13D/G
3/4/5
Arie Belldegrun, M.D. · Director
|
5.4%
|
$32,857,975
13,466,383 shares
|
+$532,440 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.3%
from 13D/G
|
$46,582,273
19,091,095 shares
|
— | 31 Mar 2026 |
| David D. Chang |
13D/G
3/4/5
David D. Chang, M.D., Ph.D. · President and CEO, Director
|
4.9%
|
$30,005,544
12,297,354 shares
|
+$478,560 | 31 Mar 2026 |
| FMR LLC |
13D/G
13F
Company
|
4.9%
|
$15,747,811
10,225,851 shares
|
-$20,861,062 | 28 Feb 2025 |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
4.7%
|
$39,540,947
16,205,306 shares
|
$0 | 16 Apr 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
774,253
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
207
Q2 2026 holders
3
Holder diff
-204
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend